Clara Mayo

Randomized, Phase III Study of Gemcitabine or Erlotinib Maintenance Therapy Versus Observation, With Predefined Second-Line Treatment, After Cisplatin-Gemcitabine Induction Chemotherapy in Advanced Non–Small-Cell Lung Cancer

First-Line Gefitinib for Patients With Advanced Non–Small-Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutations Without Indication for Chemotherapy

NMR-based metabolic profiling of human hepatoma cells in relation to cell growth by culture media analysis

First-Line Afatinib versus Chemotherapy in Patients with Non–Small Cell Lung Cancer and Common Epidermal Growth Factor Receptor Gene Mutations and Brain Metastases

Targeted Therapy for Brain Metastases in EGFR-Mutated and ALK-Rearranged Non-Small-Cell Lung Cancer

A view on drug resistance in cancer

First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer

Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Temporal Proteome and Lipidome Profiles Reveal Hepatitis C Virus-Associated Reprogramming of Hepatocellular Metabolism and Bioenergetics

Classification and mutation prediction from non–small cell lung cancer histopathology images using deep learning

Prognostic and predictive biomarkers in lung cancer. A review

Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial

Lung cancer: current therapies and new targeted treatments

The Evolving Landscape of Brain Metastasis

Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Assessment of EGFR Mutations in Circulating Tumor Cell Preparations from NSCLC Patients by Next Generation Sequencing: Toward a Real-Time Liquid Biopsy for Treatment

Indications and limitations of chemotherapy and targeted agents in non-small cell lung cancer brain metastases

Coming of age: ten years of next-generation sequencing technologies

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

Clinical pharmacokinetics of tyrosine kinase inhibitors

Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors: Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology

High-throughput profiling identifies clinically actionable mutations in salivary duct carcinoma

Epistemic Vigilance

Why professionals fail to catch liars and how they can improve

Treating Patients With EGFR-Sensitizing Mutations: First Line or Second Line—Is There a Difference?

Brain metastases from lung cancer responding to erlotinib: the importance ofEGFRmutation

Detection of EGFR mutations with mutation-specific antibodies in stage IV non-small-cell lung cancer

A Sensitive Method for Detecting EGFR Mutations in Non-small Cell Lung Cancer Samples with Few Tumor Cells

Methotrexate resistance in vitro is achieved by a dynamic selectionprocess of tumor cell variants emerging during treatment

KRAS Mutations in Lung Cancer

Erlotinib customization based on epidermal growth factor receptor (EGFR) mutations in stage IV non-small-cell lung cancer (NSCLC) patients (p)

Pharmacogenetics of EGFR in Lung Cancer: Perspectives and Clinical Applications

Racial differences in gaze behavior during conversations: Two systematic observational studies.